Roth Capital resumed coverage of LeMaitre (LMAT) with a Buy rating and $108 price target The firm says the company’s product portfolio vascular surgeons combined with its direct sales force of 164 reps is driving organic sales growth of 15% with favorable operating leverage. It sees upcoming catalysts for LeMaitre from RestoreFlow approvals in Ireland and Germany as well as the XenoSure vascular patch regulatory submission in China.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LMAT: